千金药业：三款产品获得药品注册证书

Core Viewpoint - Qianjin Pharmaceutical (600479) has received approval from the National Medical Products Administration for the registration of three new drugs, indicating a significant advancement in its product portfolio and potential market opportunities [1] Group 1: Drug Approvals - Qianjin Pharmaceutical and its subsidiary, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd., have received drug registration certificates for Dydrogesterone tablets, Baricitinib tablets (4mg, 2mg), and Dapagliflozin tablets (5mg, 10mg) [1] - Dydrogesterone tablets are indicated for the treatment of diseases caused by endogenous progesterone deficiency and for luteal support in assisted reproductive technology [1] - Baricitinib tablets are a Janus kinase (JAK) inhibitor that can block the activity of one or more members of the JAK kinase family, thereby inhibiting pathways that activate inflammation [1] - Dapagliflozin tablets are used for the treatment of type 2 diabetes [1]